Developer docs
API playgroundTry for free, no card

Search company profiles

Tedor Pharma, Inc.

Full company profile

uuid000chhf

Namestring
Tedor Pharma, Inc.
Legal namestring
Tedor Pharma, Inc.
Websiteurl
tedorpharma.com
Company typeenum
Private
Founded yearint
2001
Descriptiontext

Tedor Pharma, Inc., doing business as Tedor Pharma Services and TEDOR Pharma, is a privately held US-based contract development and manufacturing organization (CDMO) founded in 2001 and headquartered in Cumberland, Rhode Island. The company provides end-to-end services for oral solid dosage form pharmaceuticals, organized around four integrated service lines: formulation and process development, GMP analytical services, clinical trial supply services, and solid dose commercial manufacturing. Its purpose-built Cumberland facility is FDA registered and inspected, DEA licensed to manufacture controlled substances schedules II through V, and houses both pilot and commercial-scale equipment to support seamless scale-up. The firm focuses on difficult-to-formulate products, including poorly soluble APIs, high-potency compounds, multi-API combinations, and modified/extended-release formulations.

Tedor generates revenue through project-based quoting on multi-year contracts with pharmaceutical clients, priced per engagement rather than on disclosed unit rates. Its customer base spans virtual pharma companies that lack internal manufacturing, generic pharmaceutical developers pursuing ANDA and 505(b)(2) pathways, and innovator/biotech firms needing specialized solid dose capabilities. The go-to-market is direct enterprise sales supported by content marketing, industry event participation (including CPHI Milan 2026 and Mass Bio), and email nurture. The company positions itself as a smaller, more agile alternative to larger CDMOs, emphasizing a Quality by Design milestone-based project management process, transparent communication, and regulatory credentials for controlled substances.

Leadership is led by CEO Laura Iorio, who also serves on the Board of Directors, with senior hires including a CFO/EVP and a Director of Business Development that signal a gradual move toward more institutional governance. The company is privately held with no disclosed external investors, parent company, or funding rounds, and ownership and revenue are not publicly disclosed.

Short descriptiontext

Tedor Pharma is a privately held US-based CDMO specializing in oral solid dosage form development and manufacturing, serving virtual pharma, generic, and biotech clients from its FDA-registered, DEA-licensed facility in Cumberland, Rhode Island.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCumberland, United States
HQ citystring
Cumberland
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract pharmaceutical manufacturing, oral solid dose CDMO, formulation development services, analytical method development, clinical trial supply services
Industry4 codes
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Contract Development and Manufacturing (CDMO)
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Development and Manufacturing Services
TypeProfessional Services
Description

Tedor Pharma generates revenue through providing contract development and manufacturing services for pharmaceutical companies. Services are priced on a project basis with detailed quotes provided for each engagement. Revenue comes from formulation development, analytical services, clinical trial supply, and commercial manufacturing of solid dosage drug products.

tedorpharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Pricing details1 tier
1Custom project-based pricing for pharmaceutical development and manufacturing services
ModelOtherBilling cadenceMulti-year contract
Notes

Detailed project quotes provided based on scope of work, regulatory requirements, and specific client needs. Quotes are comprehensive and include all potential scenarios to avoid scope creep.

tedorpharma.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Tedor Pharma, Inc. operates as a contract development and manufacturing organization (CDMO) providing end-to-end pharmaceutical outsourcing services focused on oral solid dosage forms. The company offers four integrated service lines: formulation and process development, GMP analytical services, clinical trial supply services, and solid dose commercial manufacturing. It supports small molecule drug products from clinical Phase II through commercialization, including controlled substances (DEA schedules II-V), high-potency products, and modified-release formulations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Development costs and times can potentially be reduced by 25% and 50% respectively when outsourcing is executed properly with the right partners
Product overview1 text field

Tedor Pharma Services is a contract development and manufacturing organization (CDMO) offering a unified platform of pharmaceutical services focused on oral solid dosage forms. The company provides an integrated service portfolio comprising Formulation & Process Development, Analytical Services, Clinical Trial Supply Services, and Solid Dose Commercial Manufacturing. These four service lines work together to deliver end-to-end outsourcing solutions, guiding small molecule drug products from IND/NDA/ANDA development through clinical trial supply to commercial-scale manufacturing, with specialized capabilities in controlled substances, high-potency products, and modified-release formulations.

Product and service4 records
1Formulation & Process Development
CategoryPharmaceutical CDMO Service
Description

Comprehensive formulation development and process optimization services for solid dosage forms, including tablets, capsules, modified-release products, and specialized delivery platforms, supporting clients from early clinical phases through commercial scale-up.

2Analytical Services
CategoryPharmaceutical CDMO Service
Description

GMP-compliant analytical testing services including method development, validation, transfer, stability-indicating assays, and quality assurance support from pre-formulation through commercialization.

3Clinical Trial Supply Services
CategoryPharmaceutical CDMO Service
Description

End-to-end clinical trial support including investigational drug product manufacturing, placebo manufacturing, clinical packaging and labeling, regulatory submission support, and logistics management for phases I-IV trials.

4Solid Dose Commercial Manufacturing
CategoryPharmaceutical CDMO Service
Description

GMP commercial manufacturing of oral solid dosage pharmaceuticals at clinical through large-scale commercial production volumes, including controlled substances, high-potency products, and modified-release formulations.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeRegional player
Description

European-headquartered CDMO with solid dose formulation and commercial manufacturing. Operates in adjacent geography but offers similar service capabilities, providing a useful benchmark on European competition.

TypeDirect peer
Description

CDMO specializing in formulation development and clinical trial manufacturing for small molecule drugs; comparable scale and customer-mix overlap with Tedor.

TypeDirect peer
Description

Small-molecule API and drug product CDMO with strong solid-oral-dose capabilities. Comparable in core technology emphasis though larger in scale than Tedor.

TypeDirect peer
Description

Mid-market solid-dose CDMO providing formulation development and commercial manufacturing services. Directly comparable in service mix, scale, and customer segments.

TypeDirect peer
Description

Global CDMO with significant clinical trial supply, packaging, and commercial manufacturing offerings for solid dose products — competes with Tedor across the clinical-to-commercial continuum.

TypeDirect peer
Description

US-based mid-sized CDMO offering formulation, analytical, and commercial manufacturing for oral solid dosage forms. Comparable in size and customer base to Tedor, with overlapping virtual pharma and biotech clients.

TypeBroad incumbent
Description

Global pharma services platform within Thermo Fisher providing formulation, analytical, clinical supply, and commercial manufacturing across multiple dosage forms. Larger incumbent competing in the same outsourced services category.

TypeBroad incumbent
Description

One of the largest global CDMOs with broad oral solid dose, softgel, and biologics capabilities. While much larger and broader than Tedor, it competes for the same biotech/pharma outsourcing dollars.

TypeDirect peer
Description

Global CDMO with dedicated oral solid dose capabilities serving biotech and generic customers. Provides formulation development through commercial manufacturing — directly overlapping Tedor's service portfolio.

TypeDirect peer
Description

Specialized solid-dose contract manufacturer with strong generic-pharma focus and analytical development capabilities, serving a similar biotech/generic customer base.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Tedor Pharma, Inc.

Pharmaceutical Contract Development and Manufacturing (CDMO)tedorpharma.com

Tedor Pharma is a privately held US-based CDMO specializing in oral solid dosage form development and manufacturing, serving virtual pharma, generic, and biotech clients from its FDA-registered, DEA-licensed facility in Cumberland, Rhode Island.

What Tedor Pharma, Inc. does

Tedor Pharma, Inc., doing business as Tedor Pharma Services and TEDOR Pharma, is a privately held US-based contract development and manufacturing organization (CDMO) founded in 2001 and headquartered in Cumberland, Rhode Island. The company provides end-to-end services for oral solid dosage form pharmaceuticals, organized around four integrated service lines: formulation and process development, GMP analytical services, clinical trial supply services, and solid dose commercial manufacturing. Its purpose-built Cumberland facility is FDA registered and inspected, DEA licensed to manufacture controlled substances schedules II through V, and houses both pilot and commercial-scale equipment to support seamless scale-up. The firm focuses on difficult-to-formulate products, including poorly soluble APIs, high-potency compounds, multi-API combinations, and modified/extended-release formulations.

Tedor generates revenue through project-based quoting on multi-year contracts with pharmaceutical clients, priced per engagement rather than on disclosed unit rates. Its customer base spans virtual pharma companies that lack internal manufacturing, generic pharmaceutical developers pursuing ANDA and 505(b)(2) pathways, and innovator/biotech firms needing specialized solid dose capabilities. The go-to-market is direct enterprise sales supported by content marketing, industry event participation (including CPHI Milan 2026 and Mass Bio), and email nurture. The company positions itself as a smaller, more agile alternative to larger CDMOs, emphasizing a Quality by Design milestone-based project management process, transparent communication, and regulatory credentials for controlled substances.

Leadership is led by CEO Laura Iorio, who also serves on the Board of Directors, with senior hires including a CFO/EVP and a Director of Business Development that signal a gradual move toward more institutional governance. The company is privately held with no disclosed external investors, parent company, or funding rounds, and ownership and revenue are not publicly disclosed.

Tedor Pharma, Inc. firmographics

Firmographics
Name
Tedor Pharma, Inc.
Legal name
Tedor Pharma, Inc.
Website
https://tedorpharma.com
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
11–50 employees
Short description
Tedor Pharma is a privately held US-based CDMO specializing in oral solid dosage form development and manufacturing, serving virtual pharma, generic, and biotech clients from its FDA-registered, DEA-licensed facility in Cumberland, Rhode Island.
Ownership category
akta.pro rank

Tedor Pharma, Inc. industry classification

Industry
Product category
Pharmaceutical Contract Development and Manufacturing (CDMO)
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Contract pharmaceutical manufacturing
  • Oral solid dose CDMO
  • Formulation development services
  • Analytical method development
  • Clinical trial supply services

Where Tedor Pharma, Inc. is headquartered

Location

Headquarters

HQ city
Cumberland
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Tedor Pharma, Inc. business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Development and Manufacturing Services: Tedor Pharma generates revenue through providing contract development and manufacturing services for pharmaceutical companies. Services are priced on a project basis with detailed quotes provided for each engagement. Revenue comes from formulation development, analytical services, clinical trial supply, and commercial manufacturing of solid dosage drug products.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based pricing for pharmaceutical development and manufacturing services

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Tedor Pharma, Inc. product offering

Product offering

Core offering

Tedor Pharma, Inc. operates as a contract development and manufacturing organization (CDMO) providing end-to-end pharmaceutical outsourcing services focused on oral solid dosage forms. The company offers four integrated service lines: formulation and process development, GMP analytical services, clinical trial supply services, and solid dose commercial manufacturing. It supports small molecule drug products from clinical Phase II through commercialization, including controlled substances (DEA schedules II-V), high-potency products, and modified-release formulations.

Product overview

Tedor Pharma Services is a contract development and manufacturing organization (CDMO) offering a unified platform of pharmaceutical services focused on oral solid dosage forms. The company provides an integrated service portfolio comprising Formulation & Process Development, Analytical Services, Clinical Trial Supply Services, and Solid Dose Commercial Manufacturing. These four service lines work together to deliver end-to-end outsourcing solutions, guiding small molecule drug products from IND/NDA/ANDA development through clinical trial supply to commercial-scale manufacturing, with specialized capabilities in controlled substances, high-potency products, and modified-release formulations.

Differentiator

Problem solved

Functional benefit

Products and services

  • Formulation & Process Development Comprehensive formulation development and process optimization services for solid dosage forms, including tablets, capsules, modified-release products, and specialized delivery platforms, supporting clients from early clinical phases through commercial scale-up.
  • Analytical Services GMP-compliant analytical testing services including method development, validation, transfer, stability-indicating assays, and quality assurance support from pre-formulation through commercialization.
  • Clinical Trial Supply Services End-to-end clinical trial support including investigational drug product manufacturing, placebo manufacturing, clinical packaging and labeling, regulatory submission support, and logistics management for phases I-IV trials.
  • Solid Dose Commercial Manufacturing GMP commercial manufacturing of oral solid dosage pharmaceuticals at clinical through large-scale commercial production volumes, including controlled substances, high-potency products, and modified-release formulations.

Quantifiable outcome

  • Development costs and times can potentially be reduced by 25% and 50% respectively when outsourcing is executed properly with the right partners

Companies that use Tedor Pharma, Inc.

Customer profile

Segments3 records

Ideal customer profiles3 records

Tedor Pharma, Inc. technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Tedor Pharma, Inc. partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Tedor Pharma, Inc. competitors and assessment

Company assessment

Regional players

  • Aenova Group: European-headquartered CDMO with solid dose formulation and commercial manufacturing. Operates in adjacent geography but offers similar service capabilities, providing a useful benchmark on European competition.

Direct peers

  • Quotient Sciences: CDMO specializing in formulation development and clinical trial manufacturing for small molecule drugs; comparable scale and customer-mix overlap with Tedor.
  • Cambrex: Small-molecule API and drug product CDMO with strong solid-oral-dose capabilities. Comparable in core technology emphasis though larger in scale than Tedor.
  • Halo Pharma: Mid-market solid-dose CDMO providing formulation development and commercial manufacturing services. Directly comparable in service mix, scale, and customer segments.
  • PCI Pharma Services: Global CDMO with significant clinical trial supply, packaging, and commercial manufacturing offerings for solid dose products — competes with Tedor across the clinical-to-commercial continuum.
  • Alcami Corporation: US-based mid-sized CDMO offering formulation, analytical, and commercial manufacturing for oral solid dosage forms. Comparable in size and customer base to Tedor, with overlapping virtual pharma and biotech clients.
  • Piramal Pharma Solutions: Global CDMO with dedicated oral solid dose capabilities serving biotech and generic customers. Provides formulation development through commercial manufacturing — directly overlapping Tedor's service portfolio.
  • Metrics Contract Services: Specialized solid-dose contract manufacturer with strong generic-pharma focus and analytical development capabilities, serving a similar biotech/generic customer base.

Broad incumbents

  • Patheon (Thermo Fisher Scientific): Global pharma services platform within Thermo Fisher providing formulation, analytical, clinical supply, and commercial manufacturing across multiple dosage forms. Larger incumbent competing in the same outsourced services category.
  • Catalent: One of the largest global CDMOs with broad oral solid dose, softgel, and biologics capabilities. While much larger and broader than Tedor, it competes for the same biotech/pharma outsourcing dollars.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Tedor Pharma, Inc. social profiles

Digital presence

Tedor Pharma, Inc. compliance and trust

Trust signal

Compliance4 records

Tedor Pharma, Inc. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tedor Pharma, Inc. leadership team

Management profile

Number of profiles

Profiles5 records

Tedor Pharma, Inc. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tedor Pharma, Inc. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tedor Pharma, Inc.

What does Tedor Pharma, Inc. do?

Tedor Pharma, Inc. operates as a contract development and manufacturing organization (CDMO) providing end-to-end pharmaceutical outsourcing services focused on oral solid dosage forms. The company offers four integrated service lines: formulation and process development, GMP analytical services, clinical trial supply services, and solid dose commercial manufacturing. It supports small molecule drug products from clinical Phase II through commercialization, including controlled substances (DEA schedules II-V), high-potency products, and modified-release formulations.

Is Tedor Pharma, Inc. a public or private company?

Tedor Pharma, Inc. is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Tedor Pharma, Inc. founded?

Tedor Pharma, Inc. was founded in 2001. It employs 11 to 50 people.

Where is Tedor Pharma, Inc. based?

Tedor Pharma, Inc. is headquartered in Cumberland, United States, in the North America region.

How does Tedor Pharma, Inc. make money?

One revenue line is on record: contract Development and Manufacturing Services.

Who are Tedor Pharma, Inc.'s main competitors?

Aenova Group is listed as a regional player. Direct peers are Quotient Sciences, Cambrex, Halo Pharma, PCI Pharma Services, Alcami Corporation, Piramal Pharma Solutions and Metrics Contract Services. Broad incumbents are Patheon (Thermo Fisher Scientific) and Catalent.

Does Tedor Pharma, Inc. have an API?

No public API is recorded for Tedor Pharma, Inc..

What industry is Tedor Pharma, Inc. in?

Tedor Pharma, Inc.'s product category is Pharmaceutical Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals